48 related articles for article (PubMed ID: 21195724)
1. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway.
Luo Q; Gu Y; Zheng W; Wu X; Gong F; Gu L; Sun Y; Xu Q
Toxicol Appl Pharmacol; 2011 Mar; 251(2):130-6. PubMed ID: 21195724
[TBL] [Abstract][Full Text] [Related]
2. Spots and stripes: pleomorphic patterning of stem cells via p-ERK-dependent cell chemotaxis shown by feather morphogenesis and mathematical simulation.
Lin CM; Jiang TX; Baker RE; Maini PK; Widelitz RB; Chuong CM
Dev Biol; 2009 Oct; 334(2):369-82. PubMed ID: 19647731
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
D'Incecco A; Andreozzi M; Ludovini V; Rossi E; Capodanno A; Landi L; Tibaldi C; Minuti G; Salvini J; Coppi E; Chella A; Fontanini G; Filice ME; Tornillo L; Incensati RM; Sani S; Crinò L; Terracciano L; Cappuzzo F
Br J Cancer; 2015 Jan; 112(1):95-102. PubMed ID: 25349974
[TBL] [Abstract][Full Text] [Related]
4. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
5. The secret ally: immunostimulation by anticancer drugs.
Galluzzi L; Senovilla L; Zitvogel L; Kroemer G
Nat Rev Drug Discov; 2012 Feb; 11(3):215-33. PubMed ID: 22301798
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Kim H; Kim SH; Kim MJ; Kim SJ; Park SJ; Chung JS; Bae JH; Kang CD
J Immunother; 2011 May; 34(4):372-81. PubMed ID: 21499124
[TBL] [Abstract][Full Text] [Related]
7. Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.
Lin CH; Lin MT; Kuo YW; Ho CC
Lung Cancer; 2014 Sep; 85(3):479-80. PubMed ID: 24999085
[TBL] [Abstract][Full Text] [Related]
8. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA; Koyama S; Carretero J; Altabef A; Tchaicha JH; Christensen CL; Mikse OR; Cherniack AD; Beauchamp EM; Pugh TJ; Wilkerson MD; Fecci PE; Butaney M; Reibel JB; Soucheray M; Cohoon TJ; Janne PA; Meyerson M; Hayes DN; Shapiro GI; Shimamura T; Sholl LM; Rodig SJ; Freeman GJ; Hammerman PS; Dranoff G; Wong KK
Cancer Discov; 2013 Dec; 3(12):1355-63. PubMed ID: 24078774
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
Jia Y; Li X; Jiang T; Zhao S; Zhao C; Zhang L; Liu X; Shi J; Qiao M; Luo J; Liu S; Han R; Su C; Ren S; Zhou C
Int J Cancer; 2019 Sep; 145(5):1432-1444. PubMed ID: 30784054
[TBL] [Abstract][Full Text] [Related]
10. Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments.
Chen S; Tang J; Liu F; Li W; Yan T; Shangguan D; Yang N; Liao D
Front Immunol; 2023; 14():1094764. PubMed ID: 36949948
[TBL] [Abstract][Full Text] [Related]
11. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.
Madeddu C; Donisi C; Liscia N; Lai E; Scartozzi M; Macciò A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742933
[TBL] [Abstract][Full Text] [Related]
12. Identification of oxazolo[4,5-g]quinazolin-2(1H)-one Derivatives as EGFR Inhibitors for Cancer Prevention.
Senthil R; Meenakshi Sundaram KK; Bupesh G; Usha S; Saravanan KM
Asian Pac J Cancer Prev; 2022 May; 23(5):1687-1697. PubMed ID: 35633554
[TBL] [Abstract][Full Text] [Related]
13. Isovitexin Inhibits Ginkgolic Acids-Induced Inflammation Through Downregulating SHP2 Activation.
Zhang Y; Qi Z; Wang W; Wang L; Cao F; Zhao L; Fang X
Front Pharmacol; 2021; 12():630320. PubMed ID: 34456714
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations.
Feng Y; Zhu G; Lang S; Hao P; Li G; Chen F; Zhuo W; Duan Y; Zhang A; Chen Z; Sun J
Front Oncol; 2021; 11():659065. PubMed ID: 34123814
[TBL] [Abstract][Full Text] [Related]
15. SBF-1 inhibits contact hypersensitivity in mice through down-regulation of T-cell-mediated responses.
Chen W; Fang X; Gao Y; Shi K; Sun L; Yu B; Luo Q; Xu Q
BMC Pharmacol Toxicol; 2019 Dec; 20(1):86. PubMed ID: 31864413
[TBL] [Abstract][Full Text] [Related]
16. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.
Ayeni D; Miller B; Kuhlmann A; Ho PC; Robles-Oteiza C; Gaefele M; Levy S; de Miguel FJ; Perry C; Guan T; Krystal G; Lockwood W; Zelterman D; Homer R; Liu Z; Kaech S; Politi K
J Immunother Cancer; 2019 Jul; 7(1):172. PubMed ID: 31291990
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib-associated severe bilateral recalcitrant keratouveitis after corneal EDTA chelation.
Zhou Z; Sambhav K; Chalam KV
Am J Ophthalmol Case Rep; 2016 Dec; 4():1-3. PubMed ID: 29503911
[TBL] [Abstract][Full Text] [Related]
18. Withasteroid B from D. metel L. regulates immune responses by modulating the JAK/STAT pathway and the IL-17
Su Y; Wang Q; Yang B; Wu L; Cheng G; Kuang H
Clin Exp Immunol; 2017 Oct; 190(1):40-53. PubMed ID: 28617942
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats.
Shan X; Zhang Y; Chen H; Dong L; Wu B; Xu T; Hu J; Liu Z; Wang W; Wu L; Feng Z; Liang G
Oncotarget; 2017 Apr; 8(16):26648-26661. PubMed ID: 28460454
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
